A Single Institutional Experience Of 49 Patients With Large Granular Lymphocytic Leukemia: Clinical And Immunophenotypic Characteristics And The Significance Of Immune Therapy

T-cell large granular lymphocytic leukemia (LGL) is a rare type of T-cell lymphomas characterized by proliferation of clonal LGL (in the amount exceeding 0.5 x 109/L) that generally have CD3+, CD8+, CD16+, CD57+, CD5+ and/or CD7+, TCRαβ+, TIA1+, granzyme B+ phenotype, as well as by chronic benign clinical course (median overall survival is >10 years). So far, first-line therapy for the disease (if it is clinically indicated, i.e. in case of anemia - hemoglobin concentration <100 g/L, thrombocytopenia <50х109/L, neutropenia <0.5х109/L, splenomegaly, recurrent infections, autoimmune disorders, B-symptoms) has not been established.